Home > Insider Trading > Filing (0001104659-20-138671)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1356576	Supernus Pharmaceuticals Inc.	SUPN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1557657	K.f. Stefan Schwabe	C/O Supernus Pharmaceuticals, Inc. 9715 Key West Avenue Rockville MD 20850	Executive Vice President & Cmo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-12-21	46,347	$12.98	49,119	No	4	M	Direct
Common Stock	Disposition	2020-12-21	46,347	$22.10	2,772	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2020-12-21	46,347	$0.00	46,347	$12.98

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2026-03-01	No	4	M	Direct

Footnotes

Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.0000 to $22.2500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The option vests in four equal annual installments beginning on March 1, 2017.